Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
STAT signaling in the pathogenesis and treatment of leukemias Lin TS; Mahajan S; Frank DAOncogene 2000[May]; 19 (21): 2496-504Leukemias continue to cause significant mortality in adults and children, and the use of standard cytotoxic chemotherapy has reached a therapeutic plateau. Thus, there is great interest in treatments directed against inappropriately activated cell signaling pathways which stimulate the uncontrolled growth of neoplastic cells. Increasing evidence suggests that the STAT signaling cascade may be one target of these therapies. Signal transducer and activator of transcription (STAT) proteins are critical in mediating the response of hematopoietic cells to a diverse spectrum of cytokines. Constitutive STAT activation is present in many malignancies and has been especially well characterized in acute and chronic leukemias. While STAT activation is a common characteristic of leukemias, the specific pattern of activated STATs and the manner by which STAT activation occurs vary with each disease. STAT tyrosine phosphorylation can occur through inappropriate Jak activation or by direct activation of an oncoprotein such as Bcr/Abl, and STAT serine phosphorylation may play an important role in leukemias as well. Thus, the STAT signaling pathway is an attractive target for therapeutic intervention, and strategies designed to inhibit STAT activation and STAT mediated gene transcription may play an important role in the next generation of anti-leukemia therapies. Oncogene (2000).|*Milk Proteins[MESH]|*Signal Transduction[MESH]|Acute Disease[MESH]|DNA-Binding Proteins/antagonists & inhibitors/*metabolism[MESH]|Humans[MESH]|Leukemia, Lymphocytic, Chronic, B-Cell/metabolism/pathology/therapy[MESH]|Leukemia, Myelogenous, Chronic, BCR-ABL Positive/metabolism/pathology/therapy[MESH]|Leukemia-Lymphoma, Adult T-Cell/metabolism/pathology/therapy[MESH]|Leukemia/*metabolism/pathology/*therapy[MESH]|STAT1 Transcription Factor[MESH]|STAT3 Transcription Factor[MESH]|STAT5 Transcription Factor[MESH]|Trans-Activators/antagonists & inhibitors/*metabolism[MESH] |
